These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31066966)

  • 21. Alterations in serum amino acid concentrations in dogs with protein-losing enteropathy.
    Kathrani A; Allenspach K; Fascetti AJ; Larsen JA; Hall EJ
    J Vet Intern Med; 2018 May; 32(3):1026-1032. PubMed ID: 29604114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Y-box protein-1/p18 fragment identifies malignancies in patients with chronic liver disease.
    Tacke F; Kanig N; En-Nia A; Kaehne T; Eberhardt CS; Shpacovitch V; Trautwein C; Mertens PR
    BMC Cancer; 2011 May; 11():185. PubMed ID: 21595987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma metabolomic profiles in liver cancer patients following stereotactic body radiotherapy.
    Ng SSW; Jang GH; Kurland IJ; Qiu Y; Guha C; Dawson LA
    EBioMedicine; 2020 Sep; 59():102973. PubMed ID: 32891936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GC-MS Based Plasma Metabolomics for Identification of Candidate Biomarkers for Hepatocellular Carcinoma in Egyptian Cohort.
    Nezami Ranjbar MR; Luo Y; Di Poto C; Varghese RS; Ferrarini A; Zhang C; Sarhan NI; Soliman H; Tadesse MG; Ziada DH; Roy R; Ressom HW
    PLoS One; 2015; 10(6):e0127299. PubMed ID: 26030804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are Metabolic Signatures Mediating the Relationship between Lifestyle Factors and Hepatocellular Carcinoma Risk? Results from a Nested Case-Control Study in EPIC.
    Assi N; Thomas DC; Leitzmann M; Stepien M; Chajès V; Philip T; Vineis P; Bamia C; Boutron-Ruault MC; Sandanger TM; Molinuevo A; Boshuizen HC; Sundkvist A; Kühn T; Travis RC; Overvad K; Riboli E; Gunter MJ; Scalbert A; Jenab M; Ferrari P; Viallon V
    Cancer Epidemiol Biomarkers Prev; 2018 May; 27(5):531-540. PubMed ID: 29563134
    [No Abstract]   [Full Text] [Related]  

  • 26. Abnormalities in Plasma Phospholipid Fatty Acid Profiles of Patients with Hepatocellular Carcinoma.
    Qiu JF; Zhang KL; Zhang XJ; Hu YJ; Li P; Shang CZ; Wan JB
    Lipids; 2015 Oct; 50(10):977-85. PubMed ID: 26294003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling.
    Patterson AD; Maurhofer O; Beyoglu D; Lanz C; Krausz KW; Pabst T; Gonzalez FJ; Dufour JF; Idle JR
    Cancer Res; 2011 Nov; 71(21):6590-600. PubMed ID: 21900402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The significance and robustness of a plasma free amino acid (PFAA) profile-based multiplex function for detecting lung cancer.
    Shingyoji M; Iizasa T; Higashiyama M; Imamura F; Saruki N; Imaizumi A; Yamamoto H; Daimon T; Tochikubo O; Mitsushima T; Yamakado M; Kimura H
    BMC Cancer; 2013 Feb; 13():77. PubMed ID: 23409863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Latent transforming growth factor-beta binding protein-1 in circulating plasma as a novel biomarker for early detection of hepatocellular carcinoma.
    Cao B; Yang L; Rong W; Feng L; Han N; Zhang K; Cheng S; Wu J; Xiao T; Gao Y
    Int J Clin Exp Pathol; 2015; 8(12):16046-54. PubMed ID: 26884881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic perturbations prior to hepatocellular carcinoma diagnosis: Findings from a prospective observational cohort study.
    Stepien M; Keski-Rahkonen P; Kiss A; Robinot N; Duarte-Salles T; Murphy N; Perlemuter G; Viallon V; Tjønneland A; Rostgaard-Hansen AL; Dahm CC; Overvad K; Boutron-Ruault MC; Mancini FR; Mahamat-Saleh Y; Aleksandrova K; Kaaks R; Kühn T; Trichopoulou A; Karakatsani A; Panico S; Tumino R; Palli D; Tagliabue G; Naccarati A; Vermeulen RCH; Bueno-de-Mesquita HB; Weiderpass E; Skeie G; Ramón Quirós J; Ardanaz E; Mokoroa O; Sala N; Sánchez MJ; Huerta JM; Winkvist A; Harlid S; Ohlsson B; Sjöberg K; Schmidt JA; Wareham N; Khaw KT; Ferrari P; Rothwell JA; Gunter M; Riboli E; Scalbert A; Jenab M
    Int J Cancer; 2021 Feb; 148(3):609-625. PubMed ID: 32734650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective evaluation of circulating hepatocytes by alpha-fetoprotein mRNA in humans during liver surgery.
    Lemoine A; Le Bricon T; Salvucci M; Azoulay D; Pham P; Raccuia J; Bismuth H; Debuire B
    Ann Surg; 1997 Jul; 226(1):43-50. PubMed ID: 9242336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma level of metastasis-associated lung adenocarcinoma transcript 1 is associated with liver damage and predicts development of hepatocellular carcinoma.
    Konishi H; Ichikawa D; Yamamoto Y; Arita T; Shoda K; Hiramoto H; Hamada J; Itoh H; Fujita Y; Komatsu S; Shiozaki A; Ikoma H; Ochiai T; Otsuji E
    Cancer Sci; 2016 Feb; 107(2):149-54. PubMed ID: 26614531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
    Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
    Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
    Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E
    Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of serum histidine and plasma tryptophan as a potential biomarker to detect clear cell renal cell carcinoma.
    Lee HO; Uzzo RG; Kister D; Kruger WD
    J Transl Med; 2017 Apr; 15(1):72. PubMed ID: 28385150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma free amino acid profiles of canine mammary gland tumors.
    Azuma K; Osaki T; Tsuka T; Imagawa T; Minami S; Okamoto Y
    J Vet Sci; 2012 Dec; 13(4):433-6. PubMed ID: 23271187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The potential of plasma thrombomodulin as a biomarker of portal vein tumor thrombus in hepatocellular carcinoma.
    Zhou J; Tang ZY; Fan J; Wu ZQ; Ji Y; Ye SL
    J Cancer Res Clin Oncol; 2001 Sep; 127(9):559-64. PubMed ID: 11570577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary nuclear magnetic resonance spectroscopy of a Bangladeshi cohort with hepatitis-B hepatocellular carcinoma: A biomarker corroboration study.
    Cox IJ; Aliev AE; Crossey MM; Dawood M; Al-Mahtab M; Akbar SM; Rahman S; Riva A; Williams R; Taylor-Robinson SD
    World J Gastroenterol; 2016 Apr; 22(16):4191-200. PubMed ID: 27122669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma amino acid levels in patients with colorectal cancers and liver cirrhosis with hepatocellular carcinoma.
    Lee JC; Chen MJ; Chang CH; Tiai YF; Lin PW; Lai HS; Wang ST
    Hepatogastroenterology; 2003; 50(53):1269-73. PubMed ID: 14571716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum amino acid levels in patients with hepatocellular carcinoma.
    Watanabe A; Higashi T; Sakata T; Nagashima H
    Cancer; 1984 Nov; 54(9):1875-82. PubMed ID: 6090002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.